Climb Bio raises $110M in private placement of common stock and pre-funded warrants

Climb Bio, Inc.

Gross proceeds of ~$110M from 9.481M shares at $9.50 and 2.106M pre-funded warrants at $9.4999 each.
Closing expected April 29; participants include RA Capital, Adage Capital, Cormorant, and others.
Proceeds to fund late-stage development of budoprutug and CLYM116 for immune-mediated diseases.
Company to file resale registration statement within 45 days after closing.

Key facts

Extracted from this filing and checked against the source text.

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

Climb Bio, Inc. issued pre-funded warrants to purchase 2,106,000 shares of warrant to certain institutional accredited investors, including an affiliate of RA Capital Management for $9.4999 per Pre-Funded Warrant.

Security: warrant
Shares: pre-funded warrants to purchase 2,106,000 shares
Purchaser: certain institutional accredited investors, including an affiliate of RA Capital Management
Consideration: $9.4999 per Pre-Funded Warrant

Exact text from the filing

to certain Investors in lieu of Shares, pre-funded warrants to purchase 2,106,000 shares of the Company’s common stock (the “Pre-Funded Warrants”) at a price of $9.4999 per Pre-Funded Warrant

View on SEC.gov

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

Climb Bio, Inc. issued 9,481,000 shares of common stock to certain institutional accredited investors, including an affiliate of RA Capital Management for $9.50 per Share.

Security: common stock
Shares: 9,481,000 shares
Purchaser: certain institutional accredited investors, including an affiliate of RA Capital Management
Consideration: $9.50 per Share

Exact text from the filing

the Company agreed to issue and sell to the Investors in a private placement an aggregate of 9,481,000 shares of the Company’s common stock, par value $0.0001 per share (the “Shares”), at a price of $9.50 per Share

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Climb Bio, Inc. entered into Securities Purchase Agreement with certain institutional accredited investors, including an affiliate of RA Capital Management valued at approximately $110.0 million (effective 2026-04-27).

Action: entry
Agreement: equity purchase
Counterparty: certain institutional accredited investors, including an affiliate of RA Capital Management
Value: approximately $110.0 million
Effective: 2026-04-27

Exact text from the filing

On April 27, 2026, Climb Bio, Inc., a Delaware corporation (the “Company”), entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain institutional accredited investors (the “Investors”), including an affiliate of RA Capital Management (“RA Capital”), pursuant to which the Company agreed to issue and sell to the Investors in a private placement an aggregate of 9,481,000 shares of the Company’s common stock

View on SEC.gov

32 equity issuances filed in the last 30 days. Browse all equity issuances →

Climb Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-183711

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.